Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Lyme Borreliosis, Nervous System

Interventions

BIOLOGICAL: VLA15 with Alum
BIOLOGICAL: VLA15 without Alum

Sponsor

Pfizer

Collaborators

[object Object]